Physician

Alan D. Haber, MD

According to 2025 Medicare claims, Alan Haber, MD (NPI: 1568570596) practices pulmonary disease in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is TEMPLE FACULTY PRACTICE PLAN, INC (NPI: 1104309889; TIN: 831002191) and primary practice location at 19111-2434.

Haber's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 372 traditional Medicare patients, billed 976 HCPCS/CPT codes, and received $79,338 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,228 prescription claims across 173 beneficiaries totaling $349,488 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 1,978 claims. Open Payments data shows 2 records totaling $148. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $249,567 to $349,488. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $21,460 to $87,821.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	292	873	$59,210
2016	373	1,141	$77,791
2017	417	1,169	$77,453
2018	380	1,027	$70,517
2019	377	1,078	$79,063
2020	335	827	$60,467
2021	353	891	$68,348
2022	333	873	$66,877
2023	352	953	$71,639
2024	372	976	$79,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	121	785	$249,567
2016	135	809	$178,028
2017	161	1,183	$242,494
2018	148	1,184	$311,557
2019	128	1,099	$278,290
2020	123	1,031	$267,135
2021	153	1,106	$325,854
2022	159	1,175	$400,637
2023	149	1,093	$338,256
2024	173	1,228	$349,488

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	88	378	$17,487
2016	157	500	$18,423
2017	261	723	$24,565
2018	408	1,039	$38,284
2019	571	1,479	$54,359
2020	753	2,156	$105,518
2021	685	1,766	$100,890
2022	724	1,831	$99,603
2023	741	1,994	$106,995
2024	750	1,978	$107,571

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	119	178	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	164	207	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	56	150	$64
94726	Test to determine lung volumes using sensors	42	43	$9
94729	Test to examine how well the lungs exchange gases	42	43	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	121	4,020	$85,538
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	106	4,020	$61,453
Breo Ellipta	Fluticasone/Vilanterol	100	3,540	$46,238
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	23	1,230	$18,736
Spiriva Respimat	Tiotropium Bromide	24	780	$12,257

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A7031	Face mask interface, replacement for full face mask, each	N	62	165	$15,020
A7030	Full face mask used with positive airway pressure device, each	N	64	174	$14,554
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	18	$13,693
A4604	Tubing with integrated heating element for use with positive airway pressure device	N	106	264	$9,613
J7682	Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams	N	N/R	11	$8,458

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$148	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan D. Haber, MD?

Tedicare shows public-source Medicare data for Alan D. Haber, MD (NPI 1568570596), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan D. Haber, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan D. Haber, MD?

Alan D. Haber, MD is linked to TEMPLE FACULTY PRACTICE PLAN, INC (billing NPI 1104309889) in the available physician profile data.

Does Alan D. Haber, MD have Open Payments data?

Alan D. Haber, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.